Dendrimer-FA Conjugation Service

Dendrimers modified with folic acid (FA) can be used as gene delivery vectors with increased transfection efficiency to selectively deliver genes to cancer cells for targeted cancer diagnosis and treatment. CD BioSciences has built a robust technology platform for dendrimer modification and product development. Our experienced scientists can help our customers develop effective dendrimer modification strategies to meet the growing global demand for dendrimers.

Introduction into FA and FR

Folic acid (FA), also known as vitamin B9, belongs to the B vitamin group and is used in the synthesis of pyrimidines and purines, leading to DNA synthesis and repair. As a molecule essential to the DNA synthesis pathway, FA is necessary for cancer cell replication. The folate receptor (FR), a glycosylphosphatidylinositol-anchored protein, has a strong affinity for FA and internalizes it through endocytosis. Three types of FR including FR-α, FR-β, and FR-γ overexpress on blood side of tumor cells, while FR on normal cells expresses on apical side of them. Due to the difference in the location of FR expression in normal and cancer cells, FA is considered as an important target for targeted cancer therapy.

Dendrimer-FA Conjugation for Cancer Diagnostics and Therapeutics

FR are expressed in many cancers, such as lung, colorectal, ovarian, breast, endometrial, and head and neck cancers, but are significantly less expressed in normal cells, making FR a target for cancer imaging and therapy. Conventional cancer treatment and diagnosis has the limitations of non-specificity and inability to efficiently distinguish between healthy and cancerous cells. Dendrimers are nano-sized three-dimensional macromolecules with a well-defined spherical structure that are widely used in various aspects of drug and gene delivery due to their multivalent and host-guest encapsulation properties. Dendrimers conjugated with FA can induce FR to increase cellular uptake and transfection efficiency and serve as a suitable carrier to selectively deliver genes to cancer cells for targeted cancer therapy and precision imaging.

Schematic illustration of dendrimer surface functionalization with FA as target and intravenous administration of targeted nanosystem. (Ghaffari M, et al., 2018)

Our Services

As a trusted CRO, CD BioSciences provides cost-effective, high-quality and hassle-free dendrimer-FA conjugation services to customers worldwide. We are committed to meeting our customers' needs in an environmentally sustainable and cost-effective manner, and to attacking all challenges with the fastest turnaround time.

Advantages of Our Services

Experienced team of scientists and technicians to support you from the beginning to the end of your project.

Customized services for your attractive projects to meet your exact needs.

Timely response and continuous communication with fast turnaround times.

High quality service and assurance that all results are subject to rigorous quality testing.

Want to Learn More?

CD BioSciences has been focusing on dendrimer modification and products development to meet the needs of our customers worldwide for dendrimers. With our sophisticated equipment and experienced scientists, we are confident that we can meet every one of your specific needs. We guarantee that all deliverables are subjected to rigorous quality testing and that project challenges are attacked with the fastest possible turnaround time. If you are interested in our services or have any additional questions, please feel free to contact us and we look forward to working with you on your attractive projects.

Reference

1. Ghaffari M, et al., Surface functionalized dendrimers as controlled-release delivery nanosystems for tumor targeting. Eur J Pharm Sci. 2018, 122: 311-330.